过去一年中添加的文章,按日期排序

Gut microbiota modification with rifaximin modulates severity of symptoms of Parkinson's disease with concomitant small intestinal bacterial overgrowth

J Korbecka, A Mulak, S Budrewicz - Parkinsonism & Related …, 2024 - prd-journal.com
7 天前 - … Background: Emerging evidence suggests the significant role of gut dysbiosis and
… axis in the pathogenesis and symptomatology of Parkinson's disease (PD). Recent studies …

[HTML][HTML] Role of Bioactives in Neurodegenerative Diseases

LC Zacharia - International Journal of Molecular Sciences, 2024 - mdpi.com
7 天前 - … Alzheimer’s and Parkinson disease. The pathophysiology of these diseases is complex
and is … Ultimately, these could be combined with other emerging therapies for increasing …

Identification and validation of a novel Parkinson-Glioma feature gene signature in glioma and Parkinson's disease

H Zhang, J Wang, N Su, N Yang, X Wang, C Li - Frontiers in Aging … - frontiersin.org
8 天前 - … The signature emerged as an independent prognostic factor for glioma OS,
surpassing the predictive performance of traditional clinical variables. Notably, we observed …

Unraveling the regulatory landscape of Parkinson disease: A molecular symphony of miRNAs, transcription factors, and high-risk genes

F Zameer, P Jain, K Khan, PP Kumar… - Neuroscience …, 2024 - Elsevier
12 天前 - … MicroRNAs (miRNAs) have emerged as critical regulators of post-transcriptional
gene … biomarkers for neurodegenerative diseases, including Parkinson's disease (PD). The …

The Evolving Landscape of Parkinson's Disease Research: Current Challenges and Future Outlook

R Tenchov, J Sasso, QA Zhou - 2024 - chemrxiv.org
12 天前 - … We also review the most discussed and emerging concepts and assess the strategies
… discussed and emerging concepts and assess the strategies to combat the disease. We …

[HTML][HTML] Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?

C Hölscher - Neuropharmacology, 2024 - Elsevier
12 天前 - … class drugs are emerging as a new treatment strategy for PD and for AD. Newer
drugs that … 3 (Movement Disorder Society-Unified Parkinson's disease rating scale) test battery …

Pharmacological inhibition of α-synuclein aggregation within liquid condensates

ST Dada, Z Toprakcioglu, MP Cali, A Rӧntgen… - 2024 - repository.cam.ac.uk
18 天前 - … aggregates characteristic of Parkinson’s disease. Emerging evidence suggests that
α-… new challenges and opportunities for drug discovery for Parkinson’s disease, which is …

[HTML][HTML] Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects

B Tong, Y Ba, Z Li, C Yang, K Su, H Qi, D Zhang… - … of Disease, 2024 - Elsevier
19 天前 - … , and emerging lipid regulatory drug targets. A better understanding of the lipidological
bases of AD and PD may pave the way for developing effective prevention and treatment …

Research progress of PROTACs for neurodegenerative diseases therapy

Z Cai, Z Yang, H Li, Y Fang - Bioorganic Chemistry, 2024 - Elsevier
19 天前 - … , including Alzheimer's disease, Parkinson's disease, and Huntington's disease,
fall … system and have emerged as a novel and efficacious approach in drug discovery. …

Theranostic Application of Nanomaterial in Human Health and Disease

A Maity, R Misra, S Kundu, K Bera… - … Biotechnology-in vivo …, 2024 - taylorfrancis.com
23 天前 - … The use of inorganic nanoparticles in drug delivery is another emerging field for
the treatment of some diseases. Some of the well-established inorganic nanomaterials for …